UBS Group
VIE

UBS Group’s Viela Bio, Inc. Common Stock VIE Stock Holding History

UBS Group’s Portfolio VIE Stock Details VIE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-3,273
Closed -$124K – 8602
2020
Q1 		$124K Sell
3,273
-3,461
-51% -$135K ﹤0.01% 5097
2019
Q4 		$183K Buy
+6,734
New +$170K ﹤0.01% 5661

Other funds holding VIE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

UBS Group's VIE Position: Q2 2020 in Review

UBS Group sold out of Viela Bio, Inc. Common Stock (VIE) in Q2 2020, closing a stake of 3,273 shares — an estimated $124K sold.

UBS Group first reported a position in VIE in Q4 2019 and held it in 2 quarters. The position peaked at $183K in Q4 2019. 65 funds tracked by Wall St. Rank hold VIE as of Q2 2020.

  • UBS Group reported no remaining Viela Bio, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
  • UBS Group sold 3,273 Viela Bio, Inc. Common Stock shares in Q2 2020, an estimated $124K.
  • UBS Group first reported a position in Viela Bio, Inc. Common Stock in Q4 2019 and held it in 2 quarters.
  • UBS Group's Viela Bio, Inc. Common Stock position peaked at $183K in Q4 2019.
  • 65 funds tracked by Wall St. Rank held Viela Bio, Inc. Common Stock as of Q2 2020.

Based on UBS Group's 13F filing for Q2 2020, filed 31 Jul 2020.